Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 4, 2005 - Issue 6
Submit an article Journal homepage
111
Views
11
CrossRef citations to date
0
Altmetric
Review

Cardiovascular disease and toxicities related to HIV infection and its therapies

Karolina M Zareba University of Rochester, School of Medicine and Dentistry, Rochester, NY 14642, USA
,
Tracie L Miller Division of Pediatric Clinical Research, Department of Pediatrics, University of Miami Leonard J. Miller School of Medicine , and Holtz Children’s Hospital of the University of Miami–Jackson Memorial Medical Center, Miami, FL 33101, USA
&
Steven E Lipshultz Department of Pediatrics, Batchelor Children's Research Institute, Mailman Center for Child Development, Sylvester Comprehensive Cancer Center, University of Miami Leonard J. Miller School of Medicine, and Holtz Childrens Hospital of the University of Miami-Jackson Memorial Medical Center, Miami, Florida, P.O. Box 016820, Miami, FL 33101, USA. [email protected]
Pages 1017-1025 | Published online: 28 Oct 2005

Bibliography

  • RAFFANTI SP, CHIARAMIDA AJ, SEN P et al.: Assessment of cardiac function in patients with the acquired immunodeficiency syndrome. Chest (1988) 93:592–594.
  • STARC TJ, LIPSHULTZ SE, EASLEY KA et al.: Incidence of cardiac abnormalities in children with human immunodeficiency virus infection: the prospective P2C2 HIV study. J. Pediatr. (2002) 141:327–334.
  • LIPSHULTZ SE, EASLEY KA, ORAV EJ et al.: Cardiovascular status of infants and children of women infected with HIV-1 (P2C2 HIV): a cohort study. Lancet (2002) 360:368–373.
  • KOLTER DP: Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy. AIDS Read (2003) 13:S5–S13.
  • CARR A, SAMARAS K, CHISHOLM DJ, COOPER DA: Abnormal fat distribution and use of protease inhibitors. Lancet (1998) 351:1736.
  • SHEPHARD RJ: Exercise, immune function and HIV infection. I Sports Med. Phys. Fitness (1998) 38(2):101–110.
  • •An interesting review of exercise in HIV-infected individuals.
  • BOZZETTE SA, AKE CE TAM HK, CHANG SW, LOUIS TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl. J. Med. (2003) 348:702–710.
  • HERSKOWITZ A, VLAHOV D, WILLOUGHBY S et al.: Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am. .1 Cardiol (1993) 71(11):955–958.
  • LIPSHULTZ SE: Dilated cardiomyopathy in HIV-infected patients. N Engl. I Med. (1998) 339:1153–1155.
  • FELKER GM, THOMPSON RE, HARE JM et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl. Med. (2000) 342:1077–1084.
  • LIPSHULTZ SE, EASLEY KA, ORAV EJ et al: Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV multicenter study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation (1998) 97:1246–1256.
  • LIPSHULTZ SE, EASLEY KA, ORAV EJ et al.: Cardiac dysfunction and mortality in HIV-infected children: the prospective P2C2 HIV multicenter atudy. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation (2000) 102:1542–1548.
  • ••Establishes the relationship betweencardiac abnormalities and mortality in HIV-infected patients.
  • PULERWITZ TC, CAPPOLA TP, FELKER GM et al: Mortality in primary and secondary myocarditis. Am. Heart (2004) 147:746–750.
  • LEBECH AM, GERSTOFT J, HESSE B, PETERSEN CL, KJAER A: Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am. Heart J. (2004) 147:482–488.
  • FISHER SD, LIPSHULTZ SE: Epidemiology of cardiovascular involvement in HIV disease and AIDS. Ann. N.11.- Acad. Li. (2001) 946:13–22.
  • FISHER SD, LIPSHULTZ SE: Cardiac disease. In: AIDS Therapy. Dolin R, Masur H, Saag MS (Eds), Churchill-Livingstone, Philadelphia, USA (2002):814–826.
  • KASTEN-SPORTES C, WEINSTEIN C: Molecular mechanisms of HIV cardiovascular disease. In: Cardiology in AIDS. Lipshultz SE (Ed.), Chapman and Hall, New York (1998):265–282.
  • CURRIE PF, GOLDMAN JH, CAFORIO AL et al: Cardiac autoimmunity in HIV related heart muscle disease. Heart (1998) 79:599–604.
  • CURRIE PF, BOON NA: Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS (2003) 17:S21–S28.
  • LUGINBUHL LM, ORAV EJ, MCINTOSH K, LIPSHULTZ SE: Cardiac morbidity and related mortality in children with HIV infection. IA/VIA (1993) 269:2869–2875.
  • AL-ATTAR I, ORAV EJ, EXIL V, VLACH SA, LIPSHULTZ SE: Predictors of cardiac morbidity and related mortality in children with acquired immunodeficiency syndrome. JACC (2003) 41:1598–605.
  • LIPSHULTZ SE, ORAV EJ, SANDERS SP, COLAN SD: Immunoglobulins and left ventricular structure and function in pediatric HIV infection. Circulation (1995) 92:2220–2225.
  • LIPSHULTZ SE, FISHER SD, LAI WW, MILLER TL: Cardiovascular monitoring and therapy for HIV-infected patients. Ann. NY Acad. Sci. (2001) 946:236–273.
  • FISHER SD, BOWLES NE, TOWBIN JA, LIPSHULTZ SE: Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS (2003) 17:S29–S35.
  • LIPSHULTZ SE, FISHER SD, LAI WW, MILLER TL: Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS (2003) 17:S96–S122.
  • ••A thorough review of therapy available toHIV patients suffering from cardiovascular disease.
  • MESA RA, EDELL ES, DUNN WF, EDWARDS WD: Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin. Proc. (1998) 73:37–45.
  • PELLICELLI AM, PALMIERI F, D'AMBROSIO C et al: Role of human immunodeficiency virus in primary pulmonary hypertension-case reports. Angiology (1998) 49(12):1005–1011.
  • SEOANE L, SHELLITO J, WELSH D, DE BOISBLANC BP: Pulmonary hypertension associated with HIV infection. South Med. J. (2001) 94(6):635–639.
  • AGUILAR RV, FARBER HW: Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am. I Respir. Grit. Care Med. (2000) 162:1846–1850.
  • HEIDENREICH PA, EISENBERG MJ, KEE LL et al: Pericardial effusion in AIDS. Incidence and survival. Circulation (1995) 92:3229–3234.
  • RERKPATTANAPIPAT R, WONGPRAPARUT N, JACOBS LE, KOTLER MN: Cardiac manifestations of acquired immunodeficiency syndrome. Arch. Intern. Med. (2000) 160:602–608.
  • GOWDA RM, KHAN IA, MEHTA NJ, GOWDA MR, SACCHI TJ, VASAVADA BC: Cardiac tamponade in patients with human immunodeficiency virus disease. Angiology (2003) 54:469–474.
  • VALENCIA ORTEGA ME, GUINEA J, ENRIQUE A, ORTEGA G, MORENO V, GONZALEZ LAHOZ J: Study of 42 cases of infective endocarditis in the HAART era in Spain. Clin. Microbiol Infect. (2003) 9:1073–1075.
  • DANIEL WG, MUGGE A, MARTIN RP et al.: Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl. J. Med. (1991) 324:795–800.
  • FANTONI M, AUTORE C, DEL BORGO C: Drugs and cardiotoxicity in HIV and AIDS. Ann. NY Acad. Li. (2001) 946:179–199.
  • WONG JCL, LIPSHULTZ SE: Cardiovascular complications of pharmacotherapeutic agents (excluding the antiretrovirals) in HIV-infected patients. In: Cardiology IP AIDS. Lipshultz SE (Ed.), Chapman and Hall, New York (1998):331–343.
  • PUGLIESE A, ISNARDI D, SAINI A et al.: Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. ./. Infect. (2000) 40:282–284.
  • DUBE MP, SPRECHER D, HENRY WK et al.: Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. (2000) 31:1216–1224.
  • CURRIER JS: Cardiovascular risk associated with HIV therapy. I Acquit: Immune. Defic. Syndr. (2002) 31:S16–S23.
  • ••A very informative review of studies investigating cardiotoxicity associated with antiretroviral therapy.
  • GRUNFELD C, KOTLER DP, HAMADEH R et al: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. (1989) 86(1):27–31.
  • PURNELL JQ, ZAMBON A, KNOPP RH et al: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS (2000) 14(1):51–57.
  • VAN DER VALK M, REISS P, MOLHUIZEN H et al: Nevirapine containing potent antiretroviral therapy results in an anti-atherogenic plasma lipid profile: results from the atlantic trial. 8th Conference on Retro viruses and Opportunistic Infections, USA (2001).
  • MAGGI P, SERIO G, EPIFANI G et al: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS (2000) 14(16):F123–F128.
  • DEPAIRON M, CHESSEX S, SUDRE P et al: Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals - focus on protease inhibitor therapy. AIDS (2001) 15(3):329–334.
  • FRIIS-MOLLER N, WEBER R, REISS P et al: Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 17:1179–1193.
  • RICKERTS V, BRODT H, STASZEWSKI S, STILLE W: Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur. J. Med. Eec. (2000) 5:329–333.
  • HOLMBERG SD, MOORMAN AC, WILLIAMSON JM et al.: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet (2002) 360: 1747-1748.
  • RHEW DC, BERNAL M, AGUILAR D, ILOEJE U, GOETZ MB: Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: A systemic review. Clin. Infect. Dis. (2003) 37:959–972.
  • BERGERSEN BM, SANDVIK L, BRUUN JN, TONSTAD S: Elecvated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur. I Clin. Microbiol Infect. Dis. (2004) 23:625–630.
  • THE DATA COLLECTION ON ADVERSE EVENTS OF ANTI-HIV DRUGS (DAD) STUDY GROUP: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl. Med. (2003) 349:1993–2003.
  • KLEIN D, SIDNEY S, HURLEY L, IRIBARREN C: Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? 6th Conference on Retro viruses and Opportunistic Infections, USA (1999).
  • MARY-KRAUSE M, COTTE L, SIMON A, PARTISANI M, COSTAGLIOLA D: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 17:2479–86.
  • SCHAMBELAN M, BENSON CA, CARR A et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. I Argun: Immune. Defic. Syndr. (2002) 31:257–275.
  • SCEVOLA D, DI MATTEO A, LANZARINI P et al: Effects of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS (2003) 17:S123–S129.
  • ORRICK JJ, STEINHART CR: Atazanavir. Ann. Pharmacother. (2004) 38. E-published ahead of print.
  • HOFFMANN C, JAEGER H: Cardiology and AIDS-HAART and the consequences. Ann. NY Acad. Sci. (2001) 946:130–144.
  • STEIN JH, KLEIN MA, BELLEHUMEUR JL et al.: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation (2001) 104:257–262.
  • DUBE MP, STEIN JH, FICHTENBAUM CJ et al: Guidelines for the evaluation and management of dylipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin. Infect. Dis. (2003) 37:613–627.
  • BENESIC A, ZILLY M, KLUGE F et al:Lipid lowering therapy with Fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: Comparison of efficacy and interaction with indinavir. Infection (2004) 32:229–233.
  • MOYLE GJ, LLOYD M, REYNOLDS B et al.: Dietary advice with or without pravastatin for the management of hypercholesterolemia associated with protease inhibitor therapy. AIDS (2001) 15:1503–8.
  • STEIN JH, MERWOOD MA, BELLEHUMEUR JL et al.: Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am. Heart .l. (2004) 147:713–724.
  • BADIOU S, DE BOEVER CM, DUPUY AM, BAILLAT V, CRISTOL JP, REYNES J: Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis (2004) 172:273–279.
  • ERIKSSEN G et al: Changes in physical fitness and changes in mortality. Lancet (1988) 352:759–62.
  • SHEPARD RJ, SHEK PN: Impact of physical activity and sport on the immune system. Rev Environ. Health. (1996) 11(3):133–147.
  • CANNON JG, FIELDING RA, FIATARONE MA, ORENCOLE SF, DINARELLO CA, EVANS WJ: Increased interleukin 1 beta in human skeletal muscle after exercise. Am. Physiol (1989) 257:R451–R455.
  • BOAS SR, JOSWIAK ML, NIXON PA et al: Effects of anaerobic exercise on the immune system in eight- to seventeen-year-old trained and untrained boys. I Pediatr. (1996) 129(6):846–855.
  • NIEMAN DC: Immune response to heavy exertion. J. Appl. Physiol (1997) 82(5):1385–1394.
  • RIGSBY LW, DISHMAN RK, JACKSON AW, MACLEAN GS, RAVEN PB: Effects of exercise training on men seropositive for the human immunodeficiency virus-1. Med. ScL Sports Exerc. (1992) 24(1):6–12.
  • LAPIERRE A: Aerobic exercise training in an AIDS risk group. Int. I Sports. Med. (1991) 12:S53–S57.
  • MUSTAFA T, SY FS, MACERA CA et al: Association between exercise and HIV disease progression in a cohort of homosexual men. Ann. Epidemiol (1999) 9(2):127–131.
  • WEISSMAN JD, CONSTANTINITIS I, HUDGINS P, WALLACE DC: 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients. Neurology (1992) 42:619–623.
  • CHAN IS, NEATON JD, SARAVOLATZ LD, CRANE LR, OSTERBERGER J: Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS. AIDS(1995) 9(10):1145–1151.
  • KOTLER DP, TIERNEY AR, WANG J, PIERSON RN Jr: Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am. I Clin. Num (1989) 50(3):444–447.
  • ROUBENOFF R, WILSON IB: Effect of resistance training on self-reported physical functioning in HIV infection. Med. Sci. Sports Exerc. (2001) 33(11):1811–1817.
  • SPENCE DW, GALANTINO ML, MOSSBERG KA, ZIMMERMAN SO: Progressive resistance exercise: effect on muscle function and anthropometry of a select AIDS population. Arch. Phys. Med. Rehabil (1990) 71 (9) : 64 4–6 4 8.
  • ROUBENOFF R, MCDERMOTT A, WOOD M, SURI J: Feasibility of increasing lean body mass in HIV-infected adults sing progressive resistance training. Med. Sci. Sports Exerc. (1998) 30(5):S183.
  • ROUBENOFF R, WEISS L, MCDERMOTT A et al.: A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS (1999) 13(11):1373–1375.
  • JONES SP, DORAN DA, LEATT PB, MAHER B, PIRMOHAMED M: Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS (2001) 15(15):2049–2051.
  • DRISCOLL SD, MEININGER GE, LAREAU MT et al: Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS (2004) 18:465–473.
  • STRINGER WW: Mechanisms of exercise limitation in HIV+ individuals. Med. Sri. Sports Exerc. (2000) 32:S412–S421.
  • ZAREBA KM, LIPSHULTZ SE: Cardiovascular complications in patients with HIV infection. Curr. Infect. Drs. Rep. (2003) 5(6):513–520.
  • SELIK RM, BYERS RH JR, DWORKIN MS: Trends in diseases reported on US death certificates that mentioned HIV infection, 1987–1999. Argun: Immune. Defic. Syndr. (2002) 29:378–387.

Websites

  • http://www.unaids.org AIDS epidemic update December 2003 (2003).
  • http://www.torsades.org Arizona center for education and research therapeutics (2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.